Category: Life Sciences

Introduction Bio-pharmaceutical companies have always had a responsibility to report adverse events (AE), whether in clinical development or post market-approval scenarios, to the Food and Drug Administration (FDA).  The COVID-19 pandemic and the race to find effective treatments for this disease has caused both the FDA and bio-pharmaceutical organizations around the world to re-imagine the […]

In this blog post, we describe the first step of a process for qualifying AWS services for use as part of GxP workloads, sometimes referred to in the industry as “whitelisting” services. AWS customers with GxP compliance requirements might want to control access to the AWS services their developers use. During the supplier assessment of […]

Co-authored by Grace Tiao, Associate Director of Computational Genomics at the Broad Institute and Erin Chu, DVM, Ph.D., Life Sciences Lead, AWS Open Data Program Today we announce that data from the Genome Aggregation Consortium (gnomAD) is available for the first time on Amazon Web Services (AWS) as part of the Registry of Open Data […]

September 8, 2021: Amazon Elasticsearch Service has been renamed to Amazon OpenSearch Service. See details. Life Science companies are witnessing substantial growth in number of Adverse Events (AE) being reported for their products. This may be due to the increase in data volumes coming from journals, articles, social media, and non-standardized data sources. Evolving regulations […]

Introduction Bringing a new drug to market is a slow and laborious process. According to Tufts Centre for the Study of Drug Development, it takes on average between 7 to 10 years and costs more than $2.5 billion to bring a new drug to market. (1) More than half of this time and capital is […]

Good practice (GxP) guidelines were established by the Food and Drug Administration (FDA) and aim to ensure organizations working in life sciences develop, manufacture, and distribute products that are safe, meet quality guidelines, and are fit for use. GxP compliance has been a part of the life sciences industry for many years and heavily influences […]

Analysis of large-scale genomic data is the foundation for developing new treatments that make personalized medicine a reality. However, access to these multi-petabyte datasets brings challenges in terms of managing storage and compute infrastructure. The scale and flexibility of AWS resources are ideal for such projects. AWS has developed a Reference Architecture for compression and […]

The Dark Data Problem Up to 80% of your organization’s medical patient data is untapped, undervalued, or unused Imagine walking into a physician’s office for a checkup. As you describe some pain you’ve been having in your left knee, the doctor barely looks up from the screen as she clatters away on the keyboard, taking […]

With over 75 launches and announcements of new services and major features during re:Invent, it can be hard for any technologist to keep track of the most relevant information for Healthcare and Life Science (HCLS) workloads. Explore the below recap of information important for HCLS customers and links to the top re:Invent breakout sessions. Top […]

The below post was written by guest author Shannon Axelrod, Senior Software Engineer at the Chan Zuckerberg Initiative. At the Chan Zuckerberg Initiative (CZI), the science team’s goal is to support the science and technology that will make it possible to cure, prevent, or manage all diseases by the end of this century. In particular, the organization […]